600267 Stock Overview
Engages in the research, development, production, and sale of biological and generic drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600267 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Zhejiang Hisun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.34 |
| 52 Week High | CN¥9.84 |
| 52 Week Low | CN¥6.43 |
| Beta | 0.42 |
| 1 Month Change | -0.60% |
| 3 Month Change | 9.31% |
| 1 Year Change | -8.95% |
| 3 Year Change | -39.12% |
| 5 Year Change | -15.84% |
| Change since IPO | 41.60% |
Recent News & Updates
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29Shareholder Returns
| 600267 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.1% | -1.0% | 0.4% |
| 1Y | -9.0% | -3.0% | 12.3% |
Return vs Industry: 600267 underperformed the CN Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: 600267 underperformed the CN Market which returned 12.3% over the past year.
Price Volatility
| 600267 volatility | |
|---|---|
| 600267 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 600267 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600267's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 8,062 | Kevin Xiao | www.hisunpharm.com |
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others.
Zhejiang Hisun Pharmaceutical Co., Ltd. Fundamentals Summary
| 600267 fundamental statistics | |
|---|---|
| Market cap | CN¥9.82b |
| Earnings (TTM) | -CN¥20.24m |
| Revenue (TTM) | CN¥9.55b |
1.0x
P/S Ratio-485.3x
P/E RatioIs 600267 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600267 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.55b |
| Cost of Revenue | CN¥5.84b |
| Gross Profit | CN¥3.70b |
| Other Expenses | CN¥3.72b |
| Earnings | -CN¥20.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 38.78% |
| Net Profit Margin | -0.21% |
| Debt/Equity Ratio | 54.6% |
How did 600267 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:51 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Hisun Pharmaceutical Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |